---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-109814"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2026-09-23T11:30:41+00:00"
generated_at: "2026-09-23T11:35:14.288393+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents regains Nasdaq bid price compliance; MVLS delisting risk remains

## Summary
- Regained compliance with Nasdaq Rule 5550(a)(2) after closing bid price held ≥$1.00 for 10 sessions ending Sept 21, 2026.
- Still non-compliant with Rule 5550(b)(2) MVLS requirement: market value below $35M minimum; deadline Dec 28, 2026.
- Company evaluating options, including raising stockholders' equity to at least $2.5M, to satisfy MVLS before deadline.
- CEO reiterates priorities: operating cash flow breakeven in H2 2026, advancing DrugSorb-ATR toward FDA approval.
- No assurance of regaining MVLS compliance or maintaining Nasdaq listing.

## SEC filing metadata
- accession: 0001104659-26-109814
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2026-09-23T11:30:41+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/0001104659-26-109814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/tm2625982d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-109814
- JSON: https://secwatch.observer/filing/0001104659-26-109814.json
- Plain text: https://secwatch.observer/filing/0001104659-26-109814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.